KYMRKymera Therapeutics, Inc.

$7B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M+114.0% YoY

Gross Profit

$73M100.0% margin

Operating Income

-$101M-138.0% margin

Net Income

-$100M-137.6% margin

EPS (Diluted)

$-2.09

Cash Flow

Operating Cash Flow

-$129M

Free Cash Flow

-$131M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$606M

Total Liabilities

$146M

Stockholders' Equity

$460M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$34M	+114.0%
Gross Profit	$73M	$34M	+114.0%
Operating Income	-$101M	-$46M	-117.1%
Net Income	-$100M	-$46M	-119.8%

KYMR FY 2021 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena